Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$244.00K$244.00K+190.5% vs Q1 2025 Net Income-$15.10M-$15.10MN/M vs Q1 2025 EPS Diluted-$0.47-$0.47N/M vs Q1 2025 Operating Income-$15,804,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Margins · derivedOperating margin-6477.0%+7964.6 pt vs Q1 2025
Net margin-6186.5%+6590.9 pt vs Q1 2025
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end